Sumitomo Pharma Presents New Clinical Data on DSP-5336 at the European Hematology Association 2024 Congress
MARLBOROUGH, Mass., June 14, 2024 /PRNewswire/ -- Sumitomo Pharma America, Inc. (SMPA) today announced the oral presentation of data from the ongoing Phase 1/2 first-in-human study of DSP-5336 in patients with relapsed or refractory acute leukemia at the European Hematology Association (EHA) 2024 Hybrid Congress. DSP-5336 is an investigational small molecule inhibitor of the menin and mixed-lineage leukemia (MLL) protein interaction, which plays key roles in biological pathways, including cell growth regulation, cell cycle control, genomic stability, bone development, and hematopoiesis.1,2,3
- Patients received oral DSP-5336 in repeating 28-day cycles at doses ranging from 40 mg to 300 mg twice-daily.
- The oral presentation at EHA included the results of 57 patients.
- To date, DSP-5336 remains well-tolerated with no dose limiting toxicity (DLT) observed and no significant cardiac signal nor treatment-related discontinuations or deaths.
- We look forward to continuing to progress the study of DSP-5336 in the hopes of improving outcomes in AML and advancing patient care."